Program Announcement

for the

Defense Health Program
Department of Defense
Congressionally Directed Medical Research Programs

Lung Cancer Research Program

Idea Development Award

Funding Opportunity Number: W81XWH-13-LCRP-IDA
Catalog of Federal Domestic Assistance Number: 12.420

SUBMISSION AND REVIEW DATES AND TIMES

• Pre-Application Submission Deadline: 5:00 p.m. Eastern time (ET), June 20, 2013
• Invitation to Submit an Application: August 2013
• Application Submission Deadline: 11:59 p.m. ET, October 16, 2013
• Peer Review: December 2013
• Programmatic Review: January 2014

This Program Announcement is one of two documents with instructions to prepare and submit an application for this funding opportunity. The second document, the General Application Instructions, is available for downloading from Grants.gov.
# TABLE OF CONTENTS

I. Funding Opportunity Description ..................................................................................... 3  
   A. Program Description ........................................................................................................3  
   B. FY13 LCRP Areas of Emphasis ......................................................................................3  
   C. Award Information .........................................................................................................3  
   D. Eligibility Information .................................................................................................3  
   E. Funding ..........................................................................................................................5  

II. Submission Information ..................................................................................................... 6  
    A. Where to Obtain the Application Package .......................................................................6  
    B. Pre-Application Submission Content and Form ..............................................................7  
    C. Application Submission Content and Form ...................................................................9  
    D. Submission Dates and Times .......................................................................................14  
    E. Other Submission Requirements .................................................................................14  

III. Application Review Information ...................................................................................... 14  
    A. Application Review and Selection Process ....................................................................14  
    B. Application Review Criteria .......................................................................................15  
    C. Recipient Qualification ...............................................................................................16  
    D. Application Review Dates .........................................................................................16  
    E. Notification of Application Review Results ..................................................................17  

IV. Administrative Actions ..................................................................................................... 17  
    A. Rejection .......................................................................................................................17  
    B. Modification ................................................................................................................17  
    C. Withdrawal ..................................................................................................................17  
    D. Withhold .....................................................................................................................18  

V. Award Administration Information ................................................................................ 18  
    A. Award Notice ...............................................................................................................18  
    B. Administrative and National Policy Requirements .......................................................18  
    C. Reporting.....................................................................................................................18  
    D. Award Transfers..........................................................................................................19  

VI. Agency Contacts ............................................................................................................. 19  
    A. CDMRP Help Desk .......................................................................................................19  
    B. Grants.gov Contact Center .........................................................................................19  

VII. Application Submission Checklist ................................................................................ 20
I. FUNDING OPPORTUNITY DESCRIPTION

A. Program Description

Applications to the Fiscal Year 2013 (FY13) Lung Cancer Research Program (LCRP) are being solicited for the Assistant Secretary of Defense for Health Affairs, Defense Health Program (DHP), by the U.S. Army Medical Research Acquisitions Activity (USAMRAA). The LCRP was initiated in fiscal year 2009 (FY09) to promote innovative and competitive research focused on the development of integrated components to identify, treat, and manage early curable lung cancer. Appropriations for the LCRP from FY09 through FY12 totaled $58 million (M). The FY13 appropriation is $10.5M.

The goal of the FY13 LCRP is to eradicate deaths from lung cancer to better the health and welfare of the military and the American public. As such, the LCRP will support and integrate research from multiple disciplines for risk assessment, early detection, diagnosis, prevention, and treatment for the control and cure of lung cancer.

B. FY13 LCRP Areas of Emphasis

To be considered for funding, applications for the FY13 LCRP Idea Development Award must address at least one of the seven Areas of Emphasis listed below.

- Identify or develop noninvasive or minimally invasive tools to improve the detection of the initial stages of lung cancer.
- Identify, develop, and/or building upon already existing tools for screening or early detection of lung cancer. Screening may include, but is not limited to, computed tomography scans, X-rays, imaging biomarkers, genetics/genomics/proteomics/metabolomics, and assessment of risk factors.
- Understand the molecular mechanisms of progression to clinically significant lung cancer.
- Understand the molecular mechanisms that lead to various subtypes of lung cancer.
- Understand predictive and prognostic markers to identify responders and nonresponders.
- Understand susceptibility or resistance to treatment.

C. Award Information

The LCRP Idea Development Award mechanism was first offered in FY12. Since then, 44 Idea Development Award applications have been received, and 4 have been recommended for funding.

The Idea Development Award promotes new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation. This award supports conceptually innovative, high-risk/high-reward research that could lead to
critical discoveries or major advancements that will accelerate progress toward eradicating deaths from lung cancer. Applications should include a well-formulated, testable hypothesis based on strong scientific rationale. Submissions from and partnerships with investigators at Military Medical Treatment Facilities, Military labs, and the Department of Veterans Affairs (VA) Medical Centers and research laboratories are encouraged.

Preliminary data to support the feasibility of the research hypotheses and research approaches are required; however, these data do not necessarily need to be in lung cancer.

Key elements of this award are as follows:

- **Innovation:** Research deemed innovative may introduce a new paradigm, challenge current paradigms, look at existing problems from new perspectives, or exhibit other uniquely creative qualities.

- **Impact:** Research that has high potential impact may lead to major advancements and significantly accelerate progress toward eradicating deaths from lung cancer.

*It is the responsibility of the PI to clearly and explicitly articulate the project’s innovation and its potential impact on lung cancer and its relevance to military beneficiaries. The project’s impact to both lung cancer research and to lung cancer patients should be articulated, even if clinical impact is not an immediate outcome.*

**New Investigator Option:** The FY13 Idea Development Award mechanism encourages applications from independent investigators in the early stages of their careers (i.e., within 10 years of their first faculty appointment, or equivalent). The New Investigator Option is designed to allow applicants early in their faculty appointments to compete for funding separately from established investigators. Applications from New Investigators and Established Investigators will be peer- and programmatically reviewed in separate groups. Principal Investigators (PIs) using the New Investigator Option are strongly encouraged to strengthen their application by collaborating with investigators experienced in lung cancer research and/or possessing other relevant expertise. It is the responsibility of the applicant to describe how collaboration will augment the PI’s expertise to best address the research question. All applicants for the New Investigator Option must meet specific eligibility criteria as described in Section I.D., Eligibility Information.

*Research involving human subjects and human anatomical substances is permitted; however, clinical trials are not allowed under this funding opportunity.* For more information on clinical trials and clinical research overall, a Human Subject Resource Document is provided on the CDMRP eReceipt System at [https://cdmrp.org/Program_Announcements_and_Forms/](https://cdmrp.org/Program_Announcements_and_Forms/). Investigators wishing to apply for funding for a clinical trial should consider submitting an application to the FY13 LCRP Clinical Exploration Award mechanism (Funding Opportunity Number: W81XWH-13-LCRP-CEA).

All investigators applying to FY13 LCRP funding opportunities are encouraged to consider leveraging resources available through the LCRP-funded Lung Cancer Biorepository Resource Network (LCBRN) ([http://www.lcbrn.org/](http://www.lcbrn.org/)) if retrospectively collected human anatomical substances or correlated data are relevant to the proposed studies.
The Congressionally Directed Medical Research Programs (CDMRP) intends that data and research resources generated under awards funded by this Program Announcement/Funding Opportunity be made available to the research community (which includes both scientific and consumer advocacy communities) and to the public at large. For additional guidance, refer to the General Application Instructions, Appendix 4, Section K.

D. Eligibility Information

Although a PI may be eligible for both the Established Investigator and New Investigator Option categories, the PI can choose only one category under which to apply. If this is the case, the choice of application category is at the PI’s discretion.

- **Established Investigator**
  
  The PI must be an independent investigator at or above the level of Assistant Professor (or equivalent).

- **New Investigator**
  
  By the application submission deadline date, the PI must have:
  
  - Not previously received a LCRP Idea Development Award or LCRP Early Investigator Synergistic Idea Award; and
  
  - Be an independent investigator at or above the level of Assistant Professor (or equivalent) and be within 10 years of his/her first faculty appointment (or equivalent) by the time of the application submission deadline. Lapses in research time or appointments as denoted in the biographical sketch may be articulated in the application.

- Graduate students and postdoctoral fellows are not eligible for this award.

- Cost sharing/matching is not an eligibility requirement.

- Organizations eligible to apply include national, international, for-profit, non-profit, public, and private organizations.

- Refer to the General Application Instructions, Appendix 1, for general eligibility information.

E. Funding

- The maximum period of performance is 2 years.

- The maximum allowable direct costs for the entire period of performance are $350,000 plus indirect costs.

- All direct and indirect costs of any subaward (subgrant or subcontract) must be included in the total direct costs of the primary award.

- The applicant may request the entire maximum funding amount for a project that may have a period of performance less than the maximum 2 years.
Regardless of the period of performance proposed, the applicant may not exceed the maximum allowable direct costs. Indirect costs shall be proposed in accordance with the organization’s negotiated rate agreement.

Refer to the General Application Instructions, Section II.C.4., for budget regulations and instructions for the Research & Related Budget. For all federal agencies or organizations collaborating with federal agencies, budget restrictions apply and are so noted in Section II.C.4. of the General Application Instructions.

In addition, for this award mechanism, direct costs:

May be requested for (not all-inclusive):

- Salary
- Research supplies
- Equipment
- Clinical research costs (other than costs for clinical trials, which are not allowed)
- Travel between collaborating organizations
- Travel costs of up to $1,800 per year to attend scientific/technical meetings

Shall not be requested for:

- Clinical trial costs

The CDMRP expects to allot approximately $2.24M of the $10.5M FY13 LCRP appropriation to fund approximately 2 Established Investigator and 2 New Investigator Idea Development Award applications, depending on the quality and number of applications received. Funding of applications received in response to this Program Announcement/Funding Opportunity is contingent upon the availability of federal funds for this program.

II. SUBMISSION INFORMATION

Submission is a two-step process requiring both (1) pre-application submission through the CDMRP eReceipt System (https://cdmrp.org/) and (2) application submission through Grants.gov (http://www.grants.gov/).

Submission of applications that are essentially identical or propose essentially the same research project to different funding opportunities within the same program and fiscal year is prohibited and will result in administrative withdrawal of the duplicative application.

A. Where to Obtain the Application Package

To obtain the complete application package, including all required forms, perform a Grants.gov (http://www.grants.gov/) basic search using the Funding Opportunity Number: W81XWH-13-LCRP-IDA.
B. Pre-Application Submission Content and Form

All pre-application components must be submitted by the PI through the CDMRP eReceipt System (https://cdmrp.org/). Because the invitation to submit an application is based on the contents of the pre-application, investigators should not change the title or research objectives after the pre-application is submitted.

PIs and organizations identified in the pre-application should be the same as those intended for the subsequent application submission. If any changes are necessary after submission of the pre-application, the PI must contact the CDMRP Help Desk at help@cdmrp.org or 301-682-5507.

The pre-application consists of the following components, which are organized in the CDMRP eReceipt System by separate tabs (refer to the General Application Instructions, Section II.B., for additional information on pre-application submission):

- **Application Information – Tab 1**
- **Application Contacts – Tab 2**
- **Collaborators and Conflicts of Interest (COI) – Tab 3**

FY13 LCRP Integration Panel (IP) members should not be involved in any pre-application or application. For questions related to IP members and pre-applications or applications, refer to Section IV.C., Withdrawal, or contact the CDMRP Help Desk at help@cdmrp.org or (301-682-5507).

- **Required Files – Tab 4**

**Preproposal Narrative (two-page limit):** The Preproposal Narrative page limit applies to text and any figures, tables, graphs, photographs, diagrams, chemical structures, pictures, pictorials, and cartoons. Inclusion of URLs that provide additional information to expand the Preproposal Narrative and could confer an unfair competitive advantage is prohibited and may result in administrative withdrawal of the application.

*Note: At this time, eReceipt is unable to read files made with Adobe Acrobat PDFMaker version 9.0 and higher.  
*The inclusion of preliminary data relevant to the proposed project, but not necessarily in lung cancer, is required.*

The Preproposal Narrative should include the following:

- **Rationale:** Clearly articulate the rationale for the project by presenting the ideas and reasoning on which the proposed work is based and how the application addresses one or more of the LCRP Areas of Emphasis, and its relevance to service members, their families, and other military beneficiaries.

- **Hypothesis or Objective:** State the hypothesis to be tested or the objective to be reached.

- **Research Approach:** State the project’s specific aims and briefly describe the experimental approach to be used for accomplishing the aims. *This award cannot be used to conduct clinical trials.*
○ **Innovation:** Describe how the proposed study is innovative.

○ **Impact:** Briefly explain the applicability of the research on lung cancer patients and describe how the proposed project will have an impact toward eradicating deaths from lung cancer.

**Pre-Application Supporting Documentation:** The items to be included as supporting documentation for the pre-application are limited to:

○ References Cited (one-page limit): List the references cited (including URLs if available) in the Preproposal Narrative using a standard reference format that includes the full citation (i.e., author[s], year published, title of reference, source of reference, volume, chapter, page numbers, and publisher, as appropriate).

○ List of Abbreviations, Acronyms, and Symbols: Provide a list of abbreviations, acronyms, and symbols used in the Preproposal Narrative.

○ PI Biographical Sketch (two-page limit): Include a biographical sketch for the PI. Biographical sketches will be reviewed administratively to confirm eligibility.

- **Submit Pre-Application – Tab 5**
  This tab must be completed for the pre-application to be accepted and processed by CDMRP.

- **Other Documents Tab**
  No additional documents are required.

**Pre-Application Screening**

*Pre-applications from New Investigators and Established Investigators will be screened in separate groups.*

- **Pre-Application Screening Criteria**
  To determine the technical merits of the pre-application and the relevance to the mission of the DHP and the LCRP, pre-applications will be screened by the LCRP IP based on the following criteria:

  ○ **Innovation:** To what degree the proposed research is highly creative and represents more than an incremental advance upon published data.

  ○ **Impact:** To what degree the proposed study could lead to critical discoveries or major advancements that will accelerate progress toward eradicating deaths from lung cancer.

  ○ **Research Approach:** To what degree the experimental approach for accomplishing the specific aims is feasible and addresses the hypothesis or objective.

  ○ **Responsiveness to Intent:** How well the proposed research idea and aims address one or more of the LCRP Areas of Emphasis and its relevance to service members, their families, and other military beneficiaries.
Notification of Pre-Application Screening Results

Following the pre-application screening, PIs will be notified as to whether or not they are invited to submit applications; however, they will not receive feedback (e.g., a critique of strengths and weaknesses) on their pre-application. The estimated timeframe for notification of invitation to submit an application is indicated on the title page of this Program Announcement/Funding Opportunity.

C. Application Submission Content and Form

Applications will not be accepted unless the PI has received notification of invitation.

Each application submission must include the completed application package of forms and attachments provided in Grants.gov for this Program Announcement/Funding Opportunity. The application package is submitted by the Authorized Organizational Representative through the Grants.gov portal (http://www.grants.gov/).

Grants.gov application package components: For the Idea Development Award, the Grants.gov application package includes the following components (refer to the General Application Instructions, Section II.C., for additional information on application submission):

1. SF 424 (R&R) Application for Federal Assistance Form: Refer to the General Application Instructions, Section II.C., for detailed information.

2. Attachments Form

   • Attachment 1: Project Narrative (10-page limit): Upload as “ProjectNarrative.pdf.” The page limit of the Project Narrative applies to text and non-text elements (e.g., figures, tables, graphs, photographs, diagrams, chemical structures, drawings, etc.) used to describe the project. Inclusion of URLs that provide additional information to expand the Project Narrative and could confer an unfair competitive advantage is prohibited and will result in administrative withdrawal of the application.

   Describe the proposed project in detail using the outline below. The inclusion of preliminary data relevant to the proposed project, but not necessarily in lung cancer, is required.

   ○ Background: Present the ideas and reasoning behind the proposed research; include relevant literature citations and preliminary data that led to the development of the proposed study. Any preliminary data provided should be from the laboratory of the PI or member(s) of the collaborating team.

   ○ Hypotheses/Objectives: State the hypotheses/study questions and overall objective(s) to be reached.

   ○ Specific Aims: Concisely explain the project’s specific aims. If this application is part of a larger study, present only tasks that this award would fund.
Research Strategy: Describe the experimental design, methods, and analyses, including appropriate controls, in sufficient detail for analysis. Address potential problem areas and present alternative methods and approaches. If human subjects or human biological samples will be used, include a detailed plan for the recruitment of subjects or the acquisition of samples. This award cannot be used to conduct clinical trials.

Collaboration (if applicable; encouraged for the New Investigator Option): Describe the specific contributions of the collaborator(s) to the research project.

Data and Statistical Analysis Plan: Describe how data will be collected and analyzed in a manner that is consistent with the study objectives. If applicable, include a complete power analysis to demonstrate that the sample size is appropriate to meet the objectives of the study.

Attachment 2: Supporting Documentation. Start each document on a new page. Combine and upload as a single file named “Support.pdf.” If documents are scanned to pdf, the lowest resolution (100 to 150 dpi) should be used. There are no page limits for any of these components unless otherwise noted. Include only those components described below; inclusion of items not requested may result in the removal of those items or administrative withdrawal of the application.

References Cited: List the references cited (including URLs if available) in the project narrative using a standard reference format that includes the full citation (i.e., author[s], year published, title of reference, source of reference, volume, chapter, page numbers, and publisher, as appropriate).

List of Abbreviations, Acronyms, and Symbols: Provide a list of abbreviations, acronyms, and symbols.

Facilities, Existing Equipment, and Other Resources: Describe the facilities and equipment available for performance of the proposed project and any additional facilities or equipment proposed for acquisition at no cost to the award. Indicate whether or not Government-furnished facilities or equipment are proposed for use. If so, reference should be made to the original or present Government award under which the facilities or equipment items are now accountable. There is no form for this information.

Publications and/or Patent Abstracts (five-document limit): Include relevant publication URLs and/or patent abstracts. If publications are not publicly available, then a copy/copies of the published manuscript(s) must be included in Attachment 2. Extra items will not be reviewed.

Letters of Organizational Support: Provide a letter (or letters, if applicable), signed by the Department Chair or appropriate organization official, confirming the laboratory space, equipment, and other resources available for the project.

Letters of Collaboration (if applicable):
   - New Investigator Option (if applicable): Provide a signed letter from each collaborating individual or organization that describes how he/she will
support the project, to include unique expertise and/or availability of and access to research resources.

– **Other:** For all other investigators, provide a signed letter from each collaborating individual or organization that will demonstrate that the PI has the support or resources necessary for the proposed work.

○ **Intellectual Property**

- **Background and Proprietary Information (if applicable):** All software and data first produced under the award are subject to a federal purpose license in accordance with applicable DoD Grant and Agreement Regulations (DoDGAR) requirements. Provide a list of all background intellectual property to be used in the project. Identify any proprietary information that will be provided to the Government and indicate whether the applicant will require a waiver of the federal purpose license.

- **Intellectual and Material Property Plan (if applicable):** Provide a plan for resolving intellectual and material property issues among participating organizations.

○ **Data and Research Resources Sharing Plan:** Describe how data and resources generated during the performance of the project will be shared with the research community. Refer to the General Application Instructions, Appendix 4, for more information about the CDMRP expectations for making data and research resources publicly available.

**Attachment 3: Technical Abstract (one-page limit):** Upload as “TechAbs.pdf.”

Technical abstracts should be written using the outline below. The technical abstract is used by all reviewers; however, programmatic reviewers do not have access to the full application and therefore rely on the technical abstract for appropriate description of the project’s key aspects.

○ **Background:** Present the ideas and reasoning behind the proposed project.

○ **Objective/hypothesis:** State the objective/hypothesis to be tested. Provide evidence or rationale that supports the objective/hypothesis.

○ **Specific Aims:** State the specific aims of the study.

○ **Study Design:** Briefly describe the study design.

○ **Innovation:** Briefly describe how the proposed project is innovative.

○ **Impact:** Summarize the potential impact of the proposed project toward the goal of eradicating deaths from lung cancer.

**Attachment 4: Lay Abstract (one-page limit):** Upload as “LayAbs.pdf.”

Lay abstracts should be written using the outline below. **Do not duplicate the technical abstract.** Minimize the use of acronyms and abbreviations, where appropriate. They lay abstract is an important component of the application review process because it addresses issues of particular interest to the consumer advocate community.
○ Describe the scientific objective and rationale for the proposed project in a manner that will be readily understood by readers without a background in science or medicine.

○ Describe the ultimate applicability of the research.
  - What types of patients will it help, and how will it help them?
  - What are the potential clinical applications, benefits, and risks? If the research is too basic for clinical applicability, describe the interim outcomes expected and their applicability to the field.
  - What is the projected time it may take to achieve a clinically relevant outcome?
  - What are the likely contributions of this study to advancing the field of lung cancer research?

- **Attachment 5: Statement of Work (SOW) (three-page limit):** Upload as “SOW.pdf.” Refer to the General Application Instructions, Section II.C., for detailed information, including guidance on appropriate SOW formats.

- **Attachment 6: Impact Statement (one-page limit):**Upload as “Impact.pdf.” Explain in detail why the proposed research project is important, as follows:

  **Describe the short-term impact:** Detail the anticipated outcome(s)/product(s) that will be directly attributed to the results of the proposed research.

  **Describe the long-term impact:** Explain the anticipated long-term gains from the proposed research, including the long-term anticipated advantages that the new understanding may ultimately contribute to the goal of eradicating deaths from lung cancer.

  **LCRP Areas of Emphasis:** Describe how the proposed research addresses at least one of the LCRP Areas of Emphasis.

- **Attachment 7: Innovation Statement (one-page limit):** Upload as “Innovation.pdf.”

  Describe how the proposed work is innovative. Investigating the next logical step or incremental advancement on published data is not considered innovative.

  The following examples of ways in which research may be innovative, although not all-inclusive, are intended to help PIs frame the innovative features of their applications:
  - Study concept – Investigation of a novel idea and/or research question that could have a significant impact on lung cancer.
  - Research method or technology – Use of novel research methods or new technologies to address a research question.
  - Novel method or technology – Development of a novel method or technology for prevention, detection, diagnosis, or treatment of lung cancer.
○ Existing methods or technologies – Application or adaptation of existing methods or technologies for novel research or clinical purposes, or for research or clinical purposes that differ fundamentally from those originally intended.

- **Attachment 8: Relevance to Military Beneficiaries Statement (one-page limit):**
  Upload as “MilBen.pdf.”

Describe the impact, either short-term or long-term, of the proposed research on the health and welfare of service members, their families, and other military beneficiaries. Describe how the study design will replicate field conditions, if appropriate. If active duty military, military families, or U.S. Veteran population(s) will be used in the proposed research project, describe the population(s), the appropriateness of the population(s) for the proposed study, and the feasibility of using the population. If a non-military population will be used for the proposed research project, explain how the population simulates the targeted population (i.e., Armed Forces, their family members, and/or the U.S. Veteran population).

- **Attachment 9: (New Investigator Option only) Eligibility Statement (one-page limit):** Upload as “Eligibility.pdf.”

Use the Eligibility Statement Template (available for download on the Full Announcement page in Grants.gov) signed by the Department Chair, Dean, or equivalent official to verify that the eligibility requirements will be met at the application submission deadline.

3. **Research & Related Senior/Key Person Profile (Expanded):** Refer to the General Application Instructions, Section II.C., for detailed information. *Note: Some of the items in this attachment may be made available for programmatic review.*

- PI Biographical Sketch (four-page limit): Upload as “Biosketch_LastName.pdf.”
- PI Previous/Current/Pending Support (no page limit): Upload as “Support_LastName.pdf.”
- Key Personnel Biographical Sketches (four-page limit each): Upload as “Biosketch_LastName.pdf.”
- Key Personnel Previous/Current/Pending Support (no page limit): Upload as “Support_LastName.pdf.”

4. **Research & Related Budget:** Refer to the General Application Instructions, Section II.C., for detailed information.

- Budget Justification (no page limit): Upload as “BudgetJustification.pdf.”

5. **Project/Performance Site Location(s) Form:** Refer to the General Application Instructions, Section II.C., for detailed information.

6. **R & R Subaward Budget Attachment(s) Form (if applicable):** Refer to the General Application Instructions, Section II.C., for detailed information.
D. Submission Dates and Times

All submission dates and times are indicated on the title page of this Program Announcement/Funding Opportunity. Pre-application and application submissions are required. Failure to meet any one of the deadlines will result in application rejection.

E. Other Submission Requirements

Refer to the General Application Instructions, Appendix 2, for detailed formatting guidelines.

All applications must be submitted through Grants.gov. Applicant organizations and all subrecipient organizations must have a Data Universal Numbering System (DUNS) number to submit applications to Grants.gov. The applicant organization must also be registered in the Entity Management functional area of the System for Award Management (SAM) with an “Active” status to submit applications through the Grants.gov portal. Refer to the General Application Instructions, Appendix 3, for information on Grants.gov requirements.

III. APPLICATION REVIEW INFORMATION

A. Application Review and Selection Process

All applications are evaluated by scientists, clinicians, and consumer advocates using a two-tier review process. The first tier is a peer review of applications against established criteria for determining technical merit. The second tier is a programmatic review that makes recommendations for funding to the Commanding General, U.S. Army Medical Research and Materiel Command (USAMRMC), based on technical merit, the relevance to the mission of the DHP and LCRP and the specific intent of the award mechanism. The highest-scoring applications from the first tier of review are not automatically recommended for funding. Additional information about the two-tier review process used by the CDMRP can be found at http://cdmrp.army.mil/about/fundingprocess.

All CDMRP review processes are conducted confidentially to maintain the integrity of the merit-based selection process. Panel members sign a non-disclosure statement that application and evaluation information will not be disclosed outside the panel. Violations of confidentiality can result in the dissolving of a panel(s) and other corrective actions. In addition, personnel at the applicant or collaborating organizations are prohibited from contacting persons involved in the review process to gain protected evaluation information or to influence the evaluation process. Violations of these prohibitions will result in the administrative withdrawal of the organization’s application. Violations by panel members or applicants that compromise the confidentiality of the review process may also result in suspension or debarment from federal awards. Furthermore, the unauthorized disclosure of confidential information of one party to another third party is a crime in accordance with Title 18 United States Code 1905.
B. Application Review Criteria

Applications from New Investigators and Established Investigators will be peer and programmatically reviewed in separate groups.

1. Peer Review: To determine technical merit, all applications will be evaluated according to the following scored criteria, which are of equal importance:

- **Innovation**
  - How the research proposes new paradigms, challenges existing paradigms, or is otherwise highly creative in one or more of the following ways: Concept or question, research methods or technologies, adaptations of existing methods or technologies, or other ways.
  - How the proposed research represents more than an incremental advance upon published data.

- **Impact**
  - To what degree the proposed study could, whether in the short- or long-term, make a significant impact on lung cancer research and/or patient care, including its potential to accelerate progress toward eradicating deaths from lung cancer.
  - How well the proposed research addresses at least one of the LCRP Areas of Emphasis.

- **Research Strategy and Feasibility**
  - How the scientific rationale supports the project and its feasibility as demonstrated by a critical review and analysis of the literature, relevant preliminary data, and logical reasoning.
  - How well the hypotheses or objectives, aims, experimental design, methods, statistical plan and analyses are developed.
  - How well the PI acknowledges potential problems and addresses alternative approaches.

- **Personnel**
  - To what degree the levels of effort by the PI and other key personnel are appropriate to ensure the success of this research effort.
  - How well the PI’s record of accomplishment demonstrates his/her ability to accomplish the proposed work.
  - **New Investigator Option only:**
    - How well the PI’s record of accomplishments demonstrates his/her potential for contributing to the lung cancer research field and completing the proposed work.
    - If applicable, how well the proposed contributions of collaborators will complement the New Investigator’s ability to perform the proposed work.
In addition, the following unscored criteria will also contribute to the overall evaluation of the application:

- **Environment**
  - To what degree the scientific environment is appropriate for the proposed research.
  - How well the research requirements are supported by the availability of and accessibility to facilities and resources (including collaborative arrangements).
  - To what degree the quality and extent of organizational support are appropriate.

- **Military Relevance**
  - How the proposed research is relevant to service members, their families, and other military beneficiaries.

- **Budget**
  - Whether the budget is appropriate for the proposed research and within the limitations of this Program Announcement/Funding Opportunity.

- **Application Presentation**
  - To what extent the writing, clarity, and presentation of the application components influenced the review.

2. **Programmatic Review:** To make funding recommendations, the following equally considered criteria are used by programmatic reviewers:

   a. **Ratings and evaluations of the peer reviewers**
   b. **Relevance to the mission of the DHP and FY13 LCRP, as evidenced by the following:**
      - Adherence to the intent of the award mechanism
      - Program portfolio composition including consideration of relevance to military beneficiaries
      - Relative impact and innovation

C. **Recipient Qualification**

For general information on required qualifications for award recipients, refer to the General Application Instructions, Appendix 1.

D. **Application Review Dates**

All application review dates and times are indicated on the title page of this Program Announcement/Funding Opportunity.
E. Notification of Application Review Results

Each PI and organization will receive notification of the funding recommendation. Each PI will receive a peer review summary statement on the strengths and weaknesses of the application.

IV. ADMINISTRATIVE ACTIONS

After receipt of pre-applications from the CDMRP eReceipt System or applications from Grants.gov, the following administrative actions may occur:

A. Rejection

The following will result in administrative rejection of the pre-application:

- Preproposal Narrative exceeds page limit.
- Preproposal Narrative is missing.

The following will result in administrative rejection of the application:

- Submission of an application for which a letter of invitation was not received.
- Project Narrative exceeds page limit.
- Project Narrative is missing.
- Budget is missing.
- Submission of the same research project to different funding opportunities within the same program and fiscal year.

B. Modification

- Pages exceeding the specified limits will be removed prior to review for all documents other than the Preproposal Narrative and Project Narrative.
- Documents not requested will be removed.
- Following the application deadline, the PI may be contacted by CDMRP via email with a request to provide certain missing supporting documents (excluding those listed in Section IV.A., Rejection). The missing documents must be provided by 5:00 p.m. ET on the second full business day following the date the email was sent. Otherwise, the application will be reviewed as submitted.

C. Withdrawal

The following may result in administrative withdrawal of the pre-application or application:

- A FY13 LCRP IP member is named as being involved in the research proposed or is found to have assisted in the pre-application or application processes including, but not limited to, concept design, application development, budget preparation, and the

- The application does not conform to this Program Announcement/Funding Opportunity description to an extent that precludes appropriate review.
- Direct costs as shown on the Research & Related Budget exceed the maximum allowed by this Program Announcement/Funding Opportunity.
- Inclusion of URLs, with the exception of links in References Cited and Publication and/or Patent Abstract sections.
- Page size is larger than 8.5 inches x 11.0 inches (approximately 21.59 cm x 27.94 cm).
- Inclusion of any employee of CDMRP review contractors in applications for funding without adequate plans to mitigate conflicts of interest. Refer to the General Application Instructions, Section II.B., for detailed information.
- Personnel from applicant or collaborating organizations are found to have contacted persons involved in the review process to gain protected evaluation information or to influence the evaluation process.
- The proposed research is, or requests funding for, a clinical trial.
- The PI does not meet the eligibility criteria.
- The application does not address at least one of the LCRP Areas of Emphasis.

D. Withhold

Applications that appear to involve research misconduct will be administratively withheld from further consideration pending institutional investigation. The institution will be required to provide the findings of the investigation to the USAMRAA Grants Officer for a determination of the final disposition of the application.

V. AWARD ADMINISTRATION INFORMATION

A. Award Notice

Awards will be made no later than September 30, 2014. Refer to the General Application Instructions, Appendix 4, for additional award administration information.

B. Administrative and National Policy Requirements

Refer to the General Application Instructions, Appendix 4, Section D, for general information regarding administrative and national policy requirements.

C. Reporting

Refer to the General Application Instructions, Appendix 4, Section E, for general information on reporting requirements.
D. **Award Transfers**

Changes in PI are not allowed, except under extenuating circumstances that will be evaluated on a case-by-case basis and at the discretion of the Grants Officer.

Refer to the General Application Instructions, Appendix 4, Section F, for general information on organization or PI changes.

**VI. AGENCY CONTACTS**

**A. CDMRP Help Desk**

Questions related to Program Announcement/Funding Opportunity content or submission requirements as well as questions related to the submission of the pre-application through the CDMRP eReceipt System should be directed to the CDMRP Help Desk, which is available Monday through Friday from 8:00 a.m. to 5:00 p.m. ET. Response times may vary depending upon the volume of inquiries.

- **Phone:** 301-682-5507
- **Email:** help@cdmrp.org

**B. Grants.gov Contact Center**

Questions related to application submission through the Grants.gov portal should be directed to the Grants.gov Contact Center, which is available 24 hours a day, 7 days a week (closed on U.S. federal holidays). Note that the CDMRP Help Desk is unable to provide technical assistance with Grants.gov submission.

- **Phone:** 800-518-4726
- **Email:** support@grants.gov

*Sign up on Grants.gov for “send me change notification emails” by following the link on the Synopsis page for the Program Announcement/Funding Opportunity or by responding to the prompt provided by Grants.gov when first downloading the application package. If the application package is updated or changed, the original version of the application package may not be accepted by Grants.gov.*
## VII. APPLICATION SUBMISSION CHECKLIST

<table>
<thead>
<tr>
<th>Grants.gov Application Components</th>
<th>Action</th>
<th>Completed</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SF-424 (R&amp;R) Application for Federal Assistance Form</strong></td>
<td>Complete form as instructed.</td>
<td></td>
</tr>
<tr>
<td>Attachments Form</td>
<td>Upload Project Narrative (ProjectNarrative.pdf) as Attachment 1.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Upload Supporting Documentation (Support.pdf) as Attachment 2.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Upload Technical Abstract (TechAbs.pdf) as Attachment 3.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Upload Lay Abstract (LayAbs.pdf) as Attachment 4.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Upload Statement of Work (SOW.pdf) as Attachment 5.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Upload Innovation Statement (Innovation.pdf) as Attachment 7.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Upload Relevance to Military Beneficiaries Statement (MilBen.pdf) as Attachment 8.</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>New Investigator Option Only:</strong> Upload Eligibility Statement (Eligibility.pdf) as Attachment 9.</td>
<td></td>
</tr>
<tr>
<td><strong>Research &amp; Related Senior/Key Person Profile (Expanded)</strong></td>
<td>Attach PI Biographical Sketch (Biosketch_LastName.pdf) to the appropriate field.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Attach PI Previous/Current/Pending Support (Support_LastName.pdf) to the appropriate field.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Attach Biographical Sketch (Biosketch_LastName.pdf) for each senior/key person to the appropriate field.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Attach Previous/Current/Pending Support (Support_LastName.pdf) for each senior/key person to the appropriate field.</td>
<td></td>
</tr>
<tr>
<td><strong>Research &amp; Related Budget</strong></td>
<td>Complete as instructed. Attach Budget Justification (BudgetJustification.pdf) to the appropriate field.</td>
<td></td>
</tr>
<tr>
<td><strong>Project/Performance Site Location(s) Form</strong></td>
<td>Complete form as instructed.</td>
<td></td>
</tr>
<tr>
<td><strong>R &amp; R Subaward Budget Attachment(s) Form</strong></td>
<td>Complete form as instructed.</td>
<td></td>
</tr>
</tbody>
</table>